Development of therapeutic antibodies is a long and costly process. One key indicator of whether biologic candidates will be successful is stability. Prometheus enables rapid and precise characterization of conformational and colloidal stability of any protein using tiny amounts of sample, saving users precious time and resources while enabling a deeper biophysical understanding of their molecules. During this webinar, we will discuss how Prometheus is being used for candidate selection, engineering, and formulation.
Want to see more
biologics content?
See more related content
Use light-scattering techniques to predict how your early development candidates will behave at high concentrations for the clinic
Self-association, or the tendency for a molecule to be attracted to itself, is an important assessment criterium for those concerned about how their biologic will behave in the clinic. Researchers...
17:33How to use light scattering techniques to predict your biologic’s self-association behavior at high concentrations
Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.
What to consider when adding DLS to your early biologics development workflow (FAQs and practical tips)
Dynamic Light Scattering (DLS) is a versatile and simple tool used for assessing the colloidal stability of drug candidates early in protein-based therapeutic development. Like any tool or...
13:12How biologics teams use Dynamic Light Scattering to identify leading candidates
Watch this 15 min video to learn how groups in early biologics development and formulation use Dynamic Light Scattering (DLS) to make informed decisions that de-risk downstream biologics development.
How early discovery and development teams use Dynamic Light Scattering to de-risk downstream biologics development
As a discovery or early development scientist, you’re tasked with identifying the most promising biologics candidates. Your hard work during early development enables straightforward and efficient...
Use this downloadable list of 2023 biologics conferences to select which one to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
8 biologics conferences you won’t want to miss in 2023
When you’re part of an industry that moves quickly, it’s important to keep up. You hear about biotherapeutics approvals, and big pharma news, but nothing matches the biologics conference experience.
18:48Join Thomas Schubert, CEO of 2bind, as he walks through thermal and colloidal stability experiments done on the Prometheus Panta to determine the optimal formulation buffer for a vaccine candidate.
5 experiments in biologics that can be improved with dynamic light scattering
Biologics, which are drugs and treatments derived from natural products, undergo a long development process before they reach the clinic. When you invest a lot of time and money in the process to...
How Merck KGaA uses light scattering measurements for better developability assessment of biologic therapeutics
28:21Join Dr. Brittney Mills as she explains what criteria AbbVie’s preformulation department screens for in their antibody candidates.
5 formulation changes you can evaluate with Dynamic Light Scattering to increase your biologics candidates’ success
Biologics researchers are deeply concerned with formulation. Formulation typically refers to the final development of a deliverable, biologically derived molecule (such as a protein, peptide,...
Biologics developability: learn how Merck uses Prometheus Panta to create developability profiles for their mAbs
2:34Discover how 2bind applied multi-parameter characterization from a single experiment to find the optimal buffer for a vaccine antigen target.
4:51Four integrated technologies for Biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics
Multi-parameter formulation development for an HIV-vaccine protein with direct validation of epitope binding integrity and stoichiometry
